Thiopurine Methyltransferase Deficiency and Azathioprine Intolerance in Autoimmune Hepatitis

被引:0
作者
Albert J. Czaja
Herschel A. Carpenter
机构
[1] Mayo Clinic College of Medicine,Division of Gastroenterology and Hepatology
[2] Mayo Clinic College of Medicine,Department of Laboratory Medicine and Pathology
[3] Mayo Clinic,undefined
来源
Digestive Diseases and Sciences | 2006年 / 51卷
关键词
thiopurine methyltransferase; azathioprine; autoimmune hepatitis; treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Thiopurine methyltransferase deficiency has been associated with intolerance to azathioprine. Our goals were to assess the frequency of enzyme deficiency in autoimmune hepatitis and correlate deficiency states with azathioprine intolerance. Eighty-six patients receiving azathioprine (50–150 mg daily) were evaluated for enzyme activity and azathioprine-related complications. Their findings were compared to 89 similarly treated but untested patients. Thirteen patients (15%) had low thiopurine methyltransferase levels (11.4± 0.9 U/ml RBC; range, 3.5–14.9 U/ml RBC). Azathioprine intolerance occurred as commonly in patients with normal or above normal enzyme levels as in patients with below normal levels (12% versus 15%, p = 0.7). Patients treated without enzyme testing had the same frequency of complications (9% versus 13%, p = 0.5) as tested patients. We conclude that routine screening of blood thiopurine methyltransferase levels has a low yield for identifying individual patients at risk for azathioprine toxicity during conventional low dose therapy for autoimmune hepatitis.
引用
收藏
页码:968 / 975
页数:7
相关论文
共 150 条
[41]  
Dassopoulis T(1995)Thiopurine pharmacogenetics: Clinical and molecular studies of thiopurine methyltransferase Blood 85 1897-142
[42]  
Turnbough L(2003)Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia Gut 52 140-592
[43]  
Thompson RE(2001)Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine Gut 48 591-406
[44]  
Bayless TM(1996)Rational dosing of azathioprine and 6-mercaptopurine Gut 39 401-713
[45]  
Black AJ(2000)6-mercaptopurine metabolism in Crohn’s disease: Correlation with efficacy and toxicity Gastroenterology 118 705-670
[46]  
McLeod HL(2001)Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gut 40 665-358
[47]  
Capell HA(2002)Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease Ther Drug Monit 24 351-979
[48]  
Lennard L(2003)Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate Scand J Gastroenterol 38 972-undefined
[49]  
Welch JC(undefined)Pharmacological monitoring of azathioprine therapy undefined undefined undefined-undefined
[50]  
Lilleyman JS(undefined)undefined undefined undefined undefined-undefined